{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:20:25Z","timestamp":1782793225908,"version":"3.54.5"},"reference-count":245,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejpb.2024.114323","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T01:52:30Z","timestamp":1715737950000},"page":"114323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Enhancing cancer immunotherapy: Exploring strategies to target the PD-1\/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape"],"prefix":"10.1016","volume":"200","author":[{"given":"S.S.","family":"Kirthiga Devi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidhartha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Joga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharvari Y.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vakalapudi","family":"Meghana Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabnis","family":"Chetan Dushantrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falguni","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114323_b0005","unstructured":"WHO, Cancer, in."},{"key":"10.1016\/j.ejpb.2024.114323_b0010","doi-asserted-by":"crossref","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71 (2021) 209-249.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.ejpb.2024.114323_b0015","doi-asserted-by":"crossref","first-page":"e22900","DOI":"10.1002\/jbt.22900","article-title":"The current knowledge concerning solid cancer and therapy","volume":"35","author":"Najafi","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.ejpb.2024.114323_b0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2024.114323_b0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0030","article-title":"The difficulties in cancer treatment","volume":"6","author":"Chakraborty","year":"2012","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ejpb.2024.114323_b0035","first-page":"139","article-title":"An overview of cancer treatment modalities","volume":"1","author":"Abbas","year":"2018","journal-title":"Neoplasm"},{"key":"10.1016\/j.ejpb.2024.114323_b0040","doi-asserted-by":"crossref","unstructured":"S. Charmsaz, D.M. Collins, A.S. Perry, M. Prencipe, Novel strategies for cancer treatment: highlights from the 55th IACR annual conference, in, MDPI, 2019.","DOI":"10.3390\/cancers11081125"},{"key":"10.1016\/j.ejpb.2024.114323_b0045","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.3390\/ijms21207604","article-title":"Oncolytic virotherapy in glioma tumors","volume":"21","author":"Rius-Rocabert","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0050","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ejpb.2024.114323_b0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3121\/cmr.4.3.218","article-title":"Gene therapy for cancer treatment: past, present and future","volume":"4","author":"Cross","year":"2006","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0060","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1684\/bdc.2011.1476","article-title":"Les antim\u00e9tabolites","volume":"98","author":"Lansiaux","year":"2011","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0065","doi-asserted-by":"crossref","unstructured":"D. Karati, K.R. Mahadik, P. Trivedi, D. Kumar, Alkylating agents, the road less traversed, changing anticancer therapy, Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 22 (2022) 1478-1495.","DOI":"10.2174\/1871520621666210811105344"},{"key":"10.1016\/j.ejpb.2024.114323_b0070","doi-asserted-by":"crossref","unstructured":"G. Ciarimboli, Anticancer platinum drugs update, in, MDPI, 2021, pp. 1637.","DOI":"10.3390\/biom11111637"},{"key":"10.1016\/j.ejpb.2024.114323_b0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","article-title":"Contemporary radiotherapy: Present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2024.114323_b0080","doi-asserted-by":"crossref","first-page":"62742","DOI":"10.18632\/oncotarget.18409","article-title":"Improving radiotherapy in cancer treatment: Promises and challenges","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2024.114323_b0085","doi-asserted-by":"crossref","unstructured":"K. He, U. Selek, H.B. Barsoumian, D. Sezen, M.S. Ning, N. Puebla-Osorio, J.E. Schoenhals, D. Chen, C. Leuschner, M.A. Cortez, Mechanisms of action of radiotherapy and immunotherapy in lung cancer: Implications for clinical practice, in, Springer, 2022.","DOI":"10.1007\/174_2022_315"},{"key":"10.1016\/j.ejpb.2024.114323_b0090","unstructured":"E.J. Hall, A. Giaccia, Radiobiology for the radiologist. Lippincott, in, 1994."},{"key":"10.1016\/j.ejpb.2024.114323_b0095","unstructured":"A.C. Society, How Surgery is used for Cancer, in."},{"key":"10.1016\/j.ejpb.2024.114323_b0100","unstructured":"A.C. Society, How Targeted Therapies Are Used to Treat Cancer, in."},{"key":"10.1016\/j.ejpb.2024.114323_b0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: At last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0110","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1634\/theoncologist.2010-0035","article-title":"Trastuzumab","volume":"16","author":"Boekhout","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ejpb.2024.114323_b0115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejpb.2024.114323_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0297-0","article-title":"Bacteria-cancer interactions: bacteria-based cancer therapy","volume":"51","author":"Duong","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0125","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/mt.2013.183","article-title":"Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent","volume":"21","author":"Jiang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2024.114323_b0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy","volume":"93","author":"P\u00e9rez-Herrero","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0135","doi-asserted-by":"crossref","unstructured":"F.S. Hodi, S.J. O'day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363 (2010) 711-723.","DOI":"10.1056\/NEJMoa1003466"},{"key":"10.1016\/j.ejpb.2024.114323_b0140","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0155","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13205-023-03826-2","article-title":"Understanding immune checkpoints and PD-1\/PD-L1-mediated immune resistance towards tumour immunotherapy","volume":"13","author":"Singh","year":"2023","journal-title":"3 Biotech"},{"key":"10.1016\/j.ejpb.2024.114323_b0165","first-page":"3140","article-title":"CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events","volume":"13","author":"Tian","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0170","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3099","article-title":"Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial","author":"Goetze","year":"2020","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/cells9030563","article-title":"Recent progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications","volume":"9","author":"Chu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejpb.2024.114323_b0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2011.2","article-title":"Methodological and practical challenges for personalized cancer therapies","volume":"8","author":"Wistuba","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0190","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/153303460500400608","article-title":"Role of nanobiotechnology in developing personalized medicine for cancer","volume":"4","author":"Jain","year":"2005","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ejpb.2024.114323_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/6661406","article-title":"Current and future perspectives of PD-1\/PDL-1 blockade in cancer immunotherapy","volume":"2021","author":"Makuku","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0200","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2147\/DDDT.S267433","article-title":"Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy","author":"Ai","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejpb.2024.114323_b0205","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0215","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1038\/s41388-019-0700-2","article-title":"WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer","volume":"38","author":"Castagnoli","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ejpb.2024.114323_b0220","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3892\/or.2017.5399","article-title":"The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines","volume":"37","author":"Ishikawa","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejpb.2024.114323_b0225","doi-asserted-by":"crossref","first-page":"37439","DOI":"10.18632\/oncotarget.26473","article-title":"Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer","volume":"9","author":"Chakrabarti","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2024.114323_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 expression by NF-\u03baB in cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2024.114323_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2605","article-title":"Doxorubicin downregulates cell surface B7\u2013H1 expression and upregulates its nuclear expression in breast cancer cells: Role of B7\u2013H1 as an anti-apoptotic molecule","volume":"12","author":"Ghebeh","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0240","doi-asserted-by":"crossref","first-page":"eaay7785","DOI":"10.1126\/sciadv.aay7785","article-title":"Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-\u03baB inhibitor for antitumor immunotherapy","volume":"6","author":"Xiao","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejpb.2024.114323_b0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2017.06.033","article-title":"PD-1\/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges","volume":"405","author":"Meng","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2024.114323_b0250","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fonc.2020.554313","article-title":"Adverse effects of anti-PD-1\/PD-L1 therapy in non-small cell lung cancer","volume":"10","author":"Su","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0255","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122700","article-title":"Targeting antigen-presenting cells by anti\u2013PD-1 nanoparticles augments antitumor immunity","volume":"3","author":"Ordikhani","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejpb.2024.114323_b0260","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0265","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0270","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14737140.2016.1184980","article-title":"The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma","volume":"16","author":"Ornstein","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejpb.2024.114323_b0275","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0280","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2024.114323_b0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2019.10.047","article-title":"Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death","volume":"315","author":"Dai Phung","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114323_b0290","unstructured":"FDA, FDA Summary of Safety and Effectiveness Data in, 2015."},{"key":"10.1016\/j.ejpb.2024.114323_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-015-0348-2","article-title":"Microsatellite instability testing and its role in the management of colorectal cancer","volume":"16","author":"Kawakami","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0305","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.2147\/OTT.S168313","article-title":"Drug response to PD-1\/PD-L1 blockade: Based on biomarkers","author":"Chen","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.ejpb.2024.114323_b0310","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2024.114323_b0315","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41401-020-00570-8","article-title":"Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan\/JQ1 for chemo-immunotherapy","volume":"42","author":"He","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejpb.2024.114323_b0320","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2013.06.019","article-title":"Preparation, characterization and targeted delivery of serratiopeptidase immobilized on amino-functionalized magnetic nanoparticles","volume":"85","author":"Kumar","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/1061186X.2013.844157","article-title":"Chitosan-assisted immobilization of serratiopeptidase on magnetic nanoparticles, characterization and its target delivery","volume":"22","author":"Kumar","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2024.114323_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11051-013-2233-x","article-title":"Carbodiimide-mediated immobilization of serratiopeptidase on amino-, carboxyl-functionalized magnetic nanoparticles and characterization for target delivery","volume":"16","author":"Kumar","year":"2014","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0335","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejpb.2024.114323_b0340","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.07.005","article-title":"Toxicity profiles of immunotherapy","volume":"181","author":"Cousin","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114323_b0345","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0355","doi-asserted-by":"crossref","unstructured":"K.C. K\u00e4hler, J.C. Hassel, L. Heinzerling, C. Loquai, R. M\u00f6ssner, S. Ugurel, L. Zimmer, R. Gutzmer, C.S.E.C.o.t.W.G.D. Oncology, Management of side effects of immune checkpoint blockade by anti\u2010CTLA\u20104 and anti\u2010PD\u20101 antibodies in metastatic melanoma, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 14 (2016) 662-681.","DOI":"10.1111\/ddg.13047"},{"key":"10.1016\/j.ejpb.2024.114323_b0360","unstructured":"FDA, KEYTRUDA\u00ae- Prescribing Information, in, 2016."},{"key":"10.1016\/j.ejpb.2024.114323_b0365","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti\u2013PD-1\u2013related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0370","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0375","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114323_b0380","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0385","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4155\/ppa-2022-0046","article-title":"Photoresponsive liposomes: An alternative of ELISA for the detection of low quantities of target substances","volume":"12","author":"Joga","year":"2023","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.ejpb.2024.114323_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127911","article-title":"Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review","volume":"254","author":"Zhou","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2024.114323_b0395","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/nano11071727","article-title":"From nanoparticles to cancer nanomedicine: old problems with new solutions","volume":"11","author":"Chiang","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejpb.2024.114323_b0400","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/clpt.2012.12","article-title":"Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents","volume":"91","author":"Caron","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114323_b0405","unstructured":"S.C.o.C.S. (SCCS), Guidance on the Safety Assessment of Nanomaterials in Cosmetics, in, 2019."},{"key":"10.1016\/j.ejpb.2024.114323_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-021-02179-4","article-title":"Strategies for liposome drug delivery systems to improve tumor treatment efficacy","volume":"23","author":"Wang","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114323_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2022.111471","article-title":"Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy","author":"Mukherjee","year":"2022","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.ejpb.2024.114323_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2021.103649","article-title":"Hyper-branched multifunctional carbon nanotubes carrier for targeted liver cancer therapy","volume":"15","author":"Zhou","year":"2022","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.ejpb.2024.114323_b0425","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1567201819666220331094812","article-title":"DNA nanobots-emerging customized nanomedicine in oncology","volume":"20","author":"Singh","year":"2023","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114323_b0430","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s11658-022-00332-w","article-title":"Anti-cancer peptide-based therapeutic strategies in solid tumors","volume":"27","author":"Karami Fath","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejpb.2024.114323_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121651","article-title":"Synthetic polymer material modified by d-peptide and its targeted application in the treatment of non-small cell lung cancer","volume":"619","author":"Song","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0440","first-page":"193","article-title":"Tumoritropic and lymphotropic principles of macromolecular drugs","volume":"6","author":"Maeda","year":"1989","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2024.114323_b0445","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: How does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0450","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4155\/ppa-2021-0029","article-title":"Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer","volume":"11","author":"Joga","year":"2022","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.ejpb.2024.114323_b0455","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/129458","article-title":"Ligation strategies for targeting liposomal nanocarriers","volume":"2014","author":"Marqu\u00e9s-Gallego","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ejpb.2024.114323_b0460","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1021\/nl1002526","article-title":"Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting","volume":"10","author":"Brunel","year":"2010","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2024.114323_b0465","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejpb.2024.114323_b0470","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/thno.29431","article-title":"Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy","volume":"9","author":"Gao","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2024.114323_b0475","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijpharm.2018.03.029","article-title":"Nanoparticles for dendritic cell-based immunotherapy","volume":"542","author":"Tran","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0480","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2217\/nnm-2019-0397","article-title":"Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma","volume":"15","author":"Chen","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2024.114323_b0485","doi-asserted-by":"crossref","unstructured":"M. Imajo, Analysis of retinoic acid receptor signaling in colorectal cancer, Retinoid and Rexinoid Signaling: Methods and Protocols, (2019) 85-93.","DOI":"10.1007\/978-1-4939-9585-1_6"},{"key":"10.1016\/j.ejpb.2024.114323_b0490","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.01.041","article-title":"Tumor-specific antibody-mediated targeted delivery of Doxil\u00ae reduces the manifestation of auricular erythema side effect in mice","volume":"357","author":"Elbayoumi","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0495","doi-asserted-by":"crossref","unstructured":"Z. Yu, B. Yan, L. Gao, C. Dong, J. Zhong, M. DOrtenzio, B. Nguyen, S. Seong Lee, X. Hu, F. Liang, Targeted delivery of bleomycin: a comprehensive anticancer review, Curr. Cancer Drug Targets, 16 (2016) 509-521.","DOI":"10.2174\/1568009616666151130213910"},{"key":"10.1016\/j.ejpb.2024.114323_b0500","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/IJN.S231407","article-title":"Improvement of paclitaxel-associated adverse reactions (ADRs) via the use of nano-based drug delivery systems: A systematic review and network meta-analysis","author":"Chou","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2024.114323_b0505","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1021\/acsami.0c20422","article-title":"Dual-sensitive PEG-sheddable nanodrug hierarchically incorporating PD-L1 antibody and zinc phthalocyanine for improved immuno-photodynamic therapy","volume":"13","author":"Su","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2024.114323_b0510","article-title":"Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles","volume":"605","author":"Poudel","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0515","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jconrel.2018.08.011","article-title":"Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity","volume":"286","author":"Gu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114323_b0520","doi-asserted-by":"crossref","unstructured":"S.T. dos Reis, F.E. Villanova, P.M. Andrade, J. Pontes Jr, J.M. de Sousa-Canavez, A. Sa\u00f1udo, A.A. Antunes, M.F. Dall'Oglio, M. Srougi, K.R.M. Leite, Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer, in: Urologic Oncology: Seminars and Original Investigations, Elsevier, 2010, pp. 624-627.","DOI":"10.1016\/j.urolonc.2008.10.012"},{"key":"10.1016\/j.ejpb.2024.114323_b0525","doi-asserted-by":"crossref","first-page":"e0135544","DOI":"10.1371\/journal.pone.0135544","article-title":"Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients: a systematic review and meta-analysis","volume":"10","author":"Ren","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2024.114323_b0530","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1309\/49LA9XCBGWJ8F2KM","article-title":"Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer","volume":"129","author":"P\u00e9rigny","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ejpb.2024.114323_b0535","doi-asserted-by":"crossref","unstructured":"Y. Li, J. Ma, Q. Guo, F. Duan, F.a. Tang, P. Zheng, Z. Zhao, G. Lu, Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma, Dis. Esophagus, 22 (2009) 664-667.","DOI":"10.1111\/j.1442-2050.2008.00928.x"},{"key":"10.1016\/j.ejpb.2024.114323_b0540","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1016\/j.biomaterials.2010.06.061","article-title":"Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2","volume":"31","author":"Patterson","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114323_b0545","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/nar\/gkac052","article-title":"Origin of life: Protoribosome forms peptide bonds and links RNA and protein dominated worlds","volume":"50","author":"Bose","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0550","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/1061186X.2020.1853750","article-title":"Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1\/PD-L1 pathway and MAPK\/ERK\/JNK pathway for efficient treatment of colorectal cancer","volume":"29","author":"Li","year":"2021","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2024.114323_b0555","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/IJN.S175340","article-title":"PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells","volume":"14","author":"Xu","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2024.114323_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120988","article-title":"Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis","volume":"275","author":"Chen","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114323_b0565","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3390\/ijms17111942","article-title":"Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment","volume":"17","author":"Cui","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0570","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/ijc.32531","article-title":"A tumor-targeting nanomedicine carrying the p53 gene crosses the blood\u2013brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma","volume":"145","author":"Kim","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0575","unstructured":"Chemocare, Docetaxel, in."},{"key":"10.1016\/j.ejpb.2024.114323_b0580","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41467-019-13915-7","article-title":"Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer","volume":"11","author":"von Loga","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2024.114323_b0585","doi-asserted-by":"crossref","first-page":"baac004","DOI":"10.1093\/database\/baac004","article-title":"GNIFdb: A neoantigen intrinsic feature database for glioma","volume":"2022","author":"Li","year":"2022","journal-title":"Database"},{"key":"10.1016\/j.ejpb.2024.114323_b0590","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3322\/caac.21358","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejpb.2024.114323_b0595","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0600","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783236","article-title":"Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma","volume":"12","author":"Xing","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2024.114323_b0605","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.0105-2896.2005.00313.x","article-title":"Complexity, contradictions, and conundrums: Studying post-proteasomal proteolysis in HLA class I antigen presentation","volume":"207","author":"Saveanu","year":"2005","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejpb.2024.114323_b0610","first-page":"737","article-title":"HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions","volume":"58","author":"Vitale","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0615","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14728222.2021.1937123","article-title":"Reversing T-cell exhaustion in immunotherapy: A review on current approaches and limitations","volume":"25","author":"Tabana","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejpb.2024.114323_b0620","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1021\/acs.biomac.8b00305","article-title":"Glycocalyx-mimicking nanoparticles improve anti-PD-L1 cancer immunotherapy through reversion of tumor-associated macrophages","volume":"19","author":"Zhang","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2024.114323_b0625","doi-asserted-by":"crossref","first-page":"e1074374","DOI":"10.1080\/2162402X.2015.1074374","article-title":"Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity","volume":"5","author":"Li","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejpb.2024.114323_b0630","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/nn5014484","article-title":"A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival","volume":"8","author":"Kim","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2024.114323_b0635","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/nano11030661","article-title":"Advanced nanotechnology for enhancing immune checkpoint blockade therapy","volume":"11","author":"Cremolini","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejpb.2024.114323_b0640","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2217\/nnm-2018-0237","article-title":"Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes","volume":"14","author":"Wu","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2024.114323_b0645","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acs.biomac.8b01510","article-title":"Tumor microenvironmental pH and enzyme dual responsive polymer-liposomes for synergistic treatment of cancer immuno-chemotherapy","volume":"20","author":"Liu","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2024.114323_b0650","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2217\/nnm-2019-0073","article-title":"Programmed death-ligand 1 monoclonal antibody-linked immunoliposomes for synergistic efficacy of miR-130a and oxaliplatin in gastric cancers","volume":"14","author":"Wang","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2024.114323_b0655","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2024.114323_b0660","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanomatumor-intrinsic PD-L1 signals in cancer pathogenesis","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40580-018-0170-1","article-title":"Peptide\u2013nanoparticle conjugates: A next generation of diagnostic and therapeutic platforms?","volume":"5","author":"Jeong","year":"2018","journal-title":"Nano Convergence"},{"key":"10.1016\/j.ejpb.2024.114323_b0670","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1021\/ja211035w","article-title":"Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles","volume":"134","author":"Pan","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2024.114323_b0675","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1021\/ja0296935","article-title":"Multifunctional gold nanoparticle\u2212 peptide complexes for nuclear targeting","volume":"125","author":"Tkachenko","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2024.114323_b0680","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1039\/C6SC04293G","article-title":"Nuclear-targeted siRNA delivery for long-term gene silencing","volume":"8","author":"Li","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0685","doi-asserted-by":"crossref","first-page":"9388","DOI":"10.1021\/acsami.6b16378","article-title":"Transdermal gene delivery by functional peptide-conjugated cationic gold nanoparticle reverses the progression and metastasis of cutaneous melanoma","volume":"9","author":"Niu","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2024.114323_b0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2018.08.013","article-title":"Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin","volume":"182","author":"Zou","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114323_b0695","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1016\/j.biomaterials.2010.03.010","article-title":"Translocation of cell penetrating peptide engrafted nanoparticles across skin layers","volume":"31","author":"Patlolla","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114323_b0700","doi-asserted-by":"crossref","unstructured":"J.V. Georgieva, R.P. Brinkhuis, K. Stojanov, C.A. Weijers, H. Zuilhof, F.P. Rutjes, D. Hoekstra, J.C. van Hest, I.S. Zuhorn, Peptide-mediated blood-brain barrier transport of polymersomes, (2012).","DOI":"10.1002\/ange.201202001"},{"key":"10.1016\/j.ejpb.2024.114323_b0705","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biomaterials.2014.10.034","article-title":"Enhanced blood\u2013brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system","volume":"37","author":"Yao","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114323_b0710","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000562","article-title":"The nuclear pore complex and nuclear transport","volume":"2","author":"Wente","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ejpb.2024.114323_b0715","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1021\/acs.nanolett.0c00953","article-title":"An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy","volume":"20","author":"Bu","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2024.114323_b0720","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/13543776.2016.1206527","article-title":"Inhibitors of programmed cell death 1 (PD-1): a patent review (2010\u20132015)","volume":"26","author":"Zarganes-Tzitzikas","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejpb.2024.114323_b0725","doi-asserted-by":"crossref","first-page":"72167","DOI":"10.18632\/oncotarget.20050","article-title":"Small-molecule inhibitors of PD-1\/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells","volume":"8","author":"Skalniak","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2024.114323_b0730","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijpharm.2017.11.003","article-title":"Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: A review","volume":"535","author":"Wang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0735","doi-asserted-by":"crossref","first-page":"1903881","DOI":"10.1002\/smll.201903881","article-title":"Immune checkpoint blockade mediated by a small-molecule nanoinhibitor targeting the PD-1\/PD-L1 pathway synergizes with photodynamic therapy to elicit antitumor immunity and antimetastatic effects on breast cancer","volume":"15","author":"Zhang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2024.114323_b0740","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.actbio.2021.08.013","article-title":"Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1\/PD-L1 inhibitors than the parental drug","volume":"135","author":"Shen","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2024.114323_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in PD-1\/PD-L1 pathway inhibitors: From biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2024.114323_b0750","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","article-title":"Biomarkers for the clinical use of PD-1\/PD-L1 inhibitors in non\u2013small-cell lung cancer: A review","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0755","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2024.114323_b0760","doi-asserted-by":"crossref","unstructured":"W. Zou, J.D. Wolchok, L. Chen, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations, Sci. Transl. Med., 8 (2016) 328rv324-328rv324.","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"10.1016\/j.ejpb.2024.114323_b0765","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O'Donnell","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2024.114323_b0770","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190362","article-title":"Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1\/2-AP-1 signaling pathway","volume":"39","author":"Tsai","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejpb.2024.114323_b0775","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2014.12.022","article-title":"Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) complex nanoparticles for tumor therapy","volume":"205","author":"Yu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114323_b0780","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdermsci.2006.12.011","article-title":"Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas","volume":"46","author":"Hwang","year":"2007","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0790","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2024.114323_b0795","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114323_b0800","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s11426-018-9397-5","article-title":"Precise nanomedicine for intelligent therapy of cancer","volume":"61","author":"Chen","year":"2018","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.ejpb.2024.114323_b0805","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2024.114323_b0810","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.7150\/thno.45777","article-title":"Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy","volume":"11","author":"Cai","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2024.114323_b0815","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0820","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1158\/1078-0432.CCR-13-0583","article-title":"New strategies for triple-negative breast cancer\u2014deciphering the heterogeneity","volume":"20","author":"Mayer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0825","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and atezolizumab in triple-negative breast cancer","volume":"70","author":"Kwapisz","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejpb.2024.114323_b0830","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41419-020-2533-x","article-title":"Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?","volume":"11","author":"LaCasse","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejpb.2024.114323_b0835","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2017.74.8392","article-title":"Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial","volume":"36","author":"Bardia","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0840","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0845","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ejpb.2024.114323_b0850","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1039\/D1BM01299A","article-title":"A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy","volume":"9","author":"Gong","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0855","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.751311","article-title":"The PDAC extracellular matrix: a review of the ECM protein composition, tumor cell interaction, and therapeutic strategies","volume":"11","author":"Perez","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b0860","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2024.114323_b0865","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1039\/D0BM00916D","article-title":"Co-inhibition of the TGF-\u03b2 pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b0870","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acsnano.6b02326","article-title":"Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration","volume":"10","author":"Li","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2024.114323_b0875","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejpb.2024.114323_b0880","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1166\/jbn.2015.2069","article-title":"Polymeric nanocarriers for non-viral gene delivery","volume":"11","author":"Li","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114323_b0885","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0168-3659(99)00090-5","article-title":"Poly (ethylenimine) and its role in gene delivery","volume":"60","author":"Godbey","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114323_b0890","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.2147\/IJN.S137245","article-title":"Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer","volume":"12","author":"Luo","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2024.114323_b0895","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2147\/IJN.S112660","article-title":"Carbon nanotubes as cancer therapeutic carriers and mediators","volume":"11","author":"Son","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2024.114323_b0900","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4155\/ppa-2022-0001","article-title":"Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting","volume":"11","author":"Sabanis","year":"2022","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.ejpb.2024.114323_b0905","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jgr.2018.05.004","article-title":"The standardized Korean Red Ginseng extract and its ingredient ginsenoside Rg3 inhibit manifestation of breast cancer stem cell\u2013like properties through modulation of self-renewal signaling","volume":"43","author":"Oh","year":"2019","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0910","first-page":"1333","article-title":"Ginsenoside Rg3 enhances the anticancer effect of 5-FU in colon cancer cells via the PI3K\/AKT pathway","volume":"44","author":"Hong","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejpb.2024.114323_b0915","first-page":"17177","article-title":"Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1\/PD-L1 pathway in triple-negative breast cancer","volume":"13","author":"Luo","year":"2021","journal-title":"Aging (Albany N. Y.)"},{"key":"10.1016\/j.ejpb.2024.114323_b0920","doi-asserted-by":"crossref","first-page":"aaf5573","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2024.114323_b0925","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1126\/science.aam9321","article-title":"Nucleic acid detection with CRISPR-Cas13a\/C2c2","volume":"356","author":"Gootenberg","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2024.114323_b0930","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.celrep.2018.06.105","article-title":"RNA binding and HEPN-nuclease activation are decoupled in CRISPR-Cas13a","volume":"24","author":"Tambe","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejpb.2024.114323_b0935","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3110","article-title":"Dysregulated pH: a perfect storm for cancer progression","volume":"11","author":"Webb","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b0940","doi-asserted-by":"crossref","first-page":"1905751","DOI":"10.1002\/adma.201905751","article-title":"Dual-Locking nanoparticles disrupt the PD-1\/PD-L1 pathway for efficient cancer immunotherapy","volume":"31","author":"Zhang","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejpb.2024.114323_b0945","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition BRAF inhibition modulates PD-L1 expression in melanoma","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0950","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejpb.2024.114323_b0955","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fendo.2014.00240","article-title":"Cancer cell gene expression modulated from plasma membrane integrin \u03b1v\u03b23 by thyroid hormone and nanoparticulate tetrac","volume":"5","author":"Davis","year":"2015","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ejpb.2024.114323_b0960","doi-asserted-by":"crossref","first-page":"14735","DOI":"10.18632\/oncotarget.4023","article-title":"Thyroid hormone and anti-apoptosis in tumor cells","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2024.114323_b0965","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.steroids.2016.05.006","article-title":"Actions of l-thyroxine and nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells","volume":"114","author":"Lin","year":"2016","journal-title":"Steroids"},{"key":"10.1016\/j.ejpb.2024.114323_b0970","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1021\/acs.molpharmaceut.9b00826","article-title":"PLGA nanoparticles codelivering siRNAs against programmed cell death protein-1 and its ligand gene for suppression of colon tumor growth","volume":"16","author":"Kwak","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114323_b0975","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1128\/9781555819583.ch54","article-title":"Biologically active secondary metabolites from the fungi","author":"Bills","year":"2017","journal-title":"The Fungal Kingdom"},{"key":"10.1016\/j.ejpb.2024.114323_b0980","first-page":"105","article-title":"Impact of various factors responsible for fluctuation in plant secondary metabolites","volume":"2","author":"Verma","year":"2015","journal-title":"J. Appl. Res. Med. Aromat. Plants"},{"key":"10.1016\/j.ejpb.2024.114323_b0985","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.drudis.2016.11.015","article-title":"Recent developments in natural product-based drug discovery for tuberculosis","volume":"22","author":"Dong","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2024.114323_b0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update","author":"Engle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2024.114323_b0995","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/nu8110744","article-title":"Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth","volume":"8","author":"Ceci","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.ejpb.2024.114323_b1000","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-17-0376","article-title":"Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells","volume":"25","author":"Chin","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b1005","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3390\/molecules23082071","article-title":"Green tea catechin is an alternative immune checkpoint inhibitor that inhibits PD-L1 expression and lung tumor growth","volume":"23","author":"Rawangkan","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2024.114323_b1010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ab.2018.02.003","article-title":"PD-1\/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy","volume":"547","author":"Han","year":"2018","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejpb.2024.114323_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.05.045","article-title":"Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells","volume":"131","author":"Huang","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejpb.2024.114323_b1020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1039\/C9FO02166C","article-title":"Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-\u03baB pathway in lung adenocarcinoma","volume":"11","author":"Hu","year":"2020","journal-title":"Food Funct."},{"key":"10.1016\/j.ejpb.2024.114323_b1025","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/cells10071632","article-title":"Silibinin regulates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells","volume":"10","author":"Rugamba","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejpb.2024.114323_b1030","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.3390\/ijms21093239","article-title":"Kaempferol and its glycoside, kaempferol 7-O-rhamnoside, inhibit PD-1\/PD-L1 interaction in vitro","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114323_b1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153394","article-title":"Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells","volume":"80","author":"Yuan","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejpb.2024.114323_b1040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/biomedicines9030297","article-title":"Antitumor effects of ursolic acid through mediating the inhibition of STAT3\/PD-L1 signaling in non-small cell lung cancer cells","volume":"9","author":"Kang","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejpb.2024.114323_b1045","unstructured":"W.Y. Gao Mingxuan, Wu Chun, Bao Jing, Liang Qingle, Zhou Yang, Chen Ming, CN114432441A PD-1 modified gold composite copper selenide nano-particle and application thereof in mediating photothermal targeted therapy of cancer, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1050","unstructured":"Z.A. Xu Guangxian, Zhang Yanting, Jiang Dan, Wang Liyan, Li Yanning, CN114395046A Anti-PD-1 nano antibody, encoding gene, recombinant nano antibody, recombinant vector, recombinant strain and application, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1055","unstructured":"J.X. Li Qingpo, Zhu Chunqi, CN114272209A Nano-lipid microsphere of chemical anti-tumor drug and combined application of nano-lipid microsphere and tumor immunotherapy drug, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1060","unstructured":"H.Z. Prince Hua, CN112402622B Anti-tumor polypeptide nano-drug carrier targeting PD-L1 and application thereof, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1065","unstructured":"M.L. Qiu Qiu, Wei Xincheng, rushed towards Qian, Wang Liyun, Zhu Bi, and Li Ling, CN112121015B PD-L1 antibody-loaded bionic targeting TiO2Nano particle and its preparing method and use, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1070","unstructured":"D.B. David Stover, Bruce A. Hay, Tahmineh Safaie, US20220080051A1 Formulated and\/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1075","unstructured":"C.W. Zhen Gu, Yanqi Ye, US20220054633A1 Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1080","unstructured":"T.L. Zhang Li, Liang Chaochao, Pan Xinyuan, Wang Hui, Li Chun, Ge Shengdong, CN114010655A Gold nano star for identifying and degrading PD-L1 on surface of prostate cancer cell and preparation method and application thereof, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1085","unstructured":"W.Z. Shi Jie, Li Xia, Liu Jinlong, CN113777295A High-sensitivity quantum dot probe for detecting tumor marker PD-L1, preparation method and application, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1090","unstructured":"T.W. Liu Yanlan, Han Xiaoyan, Wang Linlin, Zhang Dailiang, Li Jili, Li Ting, Xia Yinghao, CN113730580A Application of PD-L1 inhibitor in preparation of medicine or kit, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1095","unstructured":"A.N. Rita Elena Serda, US20210330696A1 A high capacity platform for immunogenic cancer cell death, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1100","unstructured":"L. Mi, CN113440605A Conveying system for whole cell components and application thereof, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1105","unstructured":"S.N. Tang Zhaohui, Yu Haiyang, Yang Chenguang, Chen Xuesi, CN112915101A Anti-tumor combined medicine composition and application thereof, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1110","unstructured":"H.N. Wu Fenglei, Qingshuibao, Zeng Tao, Hong Yidong, Bian Baoxiang, Song Ziyan, CN112891554A Anti-tumor PD-L1 monoclonal antibody targeted drug-loaded polymer, and preparation method and application thereof, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1115","unstructured":"F.L. Guo Rui, Wen Rong, Lan Yong, Sang Shoushan, CN112870370A Targeting drug-loading system based on black phosphorus nanosheet and preparation method thereof in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1120","unstructured":"W.M. Qiu Zheng, Cheng Lu, Liu Lihua, Fei Huan, CN112807447A PD-L1 targeted sorafenib-loaded PLGA nano preparation and preparation method thereof, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1125","unstructured":"L.C. Liu Gang, CN111150716B Universal antigen self-presenting tumor vaccine and preparation method thereof, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1130","unstructured":"Z.J. Wang Xiuxiu, Zhang Jingyi, Wei Wei, Guo Zi, Jiantian, CN112494645A Application of arsenic alkene nano material and immune checkpoint inhibitor in tumor treatment in combination, in, 2021."},{"key":"10.1016\/j.ejpb.2024.114323_b1135","unstructured":"D.X. Li Zhenhua, Zhang Jinchao, CN111840528A Tumor vaccine of exosome combined immune checkpoint blocking agent and preparation method thereof, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114323_b1140","unstructured":"G.C. Guan Fei, Han Zhimin, Li Guorui, Li Juan, Tian Jing, Ding Nan, Chen Xinlu, Gu Yongwei, Zhang Yuansheng, Fu Zhiqin, Xu Youfa, CN111650382A Targeting peptide-mediated gold nanoparticle biosensor and preparation method and application thereof, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114323_b1145","unstructured":"X.W. Hu Liming, Wang Hao, CN111349145A Polypeptide molecule for preventing PD-L1 from being redistributed on tumor surface, preparation and application, in, 2020."},{"key":"10.1016\/j.ejpb.2024.114323_b1150","unstructured":"USFDA, Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer - Guidance for Industry, in, 2022."},{"key":"10.1016\/j.ejpb.2024.114323_b1155","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41401-022-00910-w","article-title":"Engineered nanomedicines block the PD-1\/PD-L1 axis for potentiated cancer immunotherapy","volume":"43","author":"Li","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejpb.2024.114323_b1160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nnm-2018-0120","article-title":"Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities","volume":"14","author":"Farjadian","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2024.114323_b1165","doi-asserted-by":"crossref","unstructured":"J. Szebeni, W. Jiskoot, Immunological issues with nanomedicines: immunogenicity, hypersensitivity, accelerated clearance and immune suppression, HANDBOOK OF NANOBIOMEDICAL RESEARCH: Fundamentals, Applications and Recent Developments: Volume 4. Biological Requirement and Safety Assessment of Nanomedicines, (2014) 45-73.","DOI":"10.1142\/9789814520652_0053"},{"key":"10.1016\/j.ejpb.2024.114323_b1170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114323_b1175","unstructured":"USFDA, Guidance for Industry: Safety of Nanomaterials in Cosmetic Products, in, 2014."},{"key":"10.1016\/j.ejpb.2024.114323_b1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122633","article-title":"Paradigm of lyotropic liquid crystals in tissue regeneration","volume":"634","author":"Shah","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114323_b1185","unstructured":"E. Commission, RIPoN, (2009)."},{"key":"10.1016\/j.ejpb.2024.114323_b1190","unstructured":"P.S.A.K. Hankin S.M., Poland C.A., Foss Hansen S., Holmqvist J., Ross B.L., Varet J. and Aitken R.J. , Specific Advice on Fulfilling Information Requirements for Nanomaterials under REACH (RIP-oN 2) in, 2011."},{"key":"10.1016\/j.ejpb.2024.114323_b1195","unstructured":"USFDA, Purple Book Database of Licensed Biological Products, in."},{"key":"10.1016\/j.ejpb.2024.114323_b1200","unstructured":"E.M. Agency, Medicines - Durvalumab, in."},{"key":"10.1016\/j.ejpb.2024.114323_b1205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/bp060348j","article-title":"Nanoparticle-mediated drug delivery and gene therapy","volume":"23","author":"Jin","year":"2007","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ejpb.2024.114323_b1210","doi-asserted-by":"crossref","unstructured":"H. Wang, I. Belitskaya-L\u00e9vy, Y. Lu, Biomarker-Targeted Confirmatory Trials, Design and Analysis of Subgroups with Biopharmaceutical Applications, (2020) 19-31.","DOI":"10.1007\/978-3-030-40105-4_2"},{"key":"10.1016\/j.ejpb.2024.114323_b1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00086","article-title":"Biomarker-driven oncology clinical trials: Key design elements, types, features, and practical considerations","volume":"1","author":"Hu","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b1220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2013.218","article-title":"Biomarker enrichment strategies: Matching trial design to biomarker credentials","volume":"11","author":"Freidlin","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2024.114323_b1225","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3390\/cells9092102","article-title":"Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology","volume":"9","author":"Bockamp","year":"2020","journal-title":"Cells"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:56:15Z","timestamp":1718603775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":245,"alternative-id":["S0939641124001498"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114323","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing cancer immunotherapy: Exploring strategies to target the PD-1\/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114323"}}